Skip to main content

Table 4 Predictors of HBV screening a by cancer type

From: Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center

Predictor

Hematologic malignancy (N = 3657)

Solid tumorb(N =15,031)

 

Screened

Univariate logistic regression

Multiple logistic regression OR

Screened

Univariate logistic regression

Multiple logistic regression

 

(N=2439) (66.7%)

OR (95% CI)

P value

(95% CI)

P value

(N=581) (3.9%)

OR (95% CI)

P value

OR (95% CI)

P value

Age, years, mean (SD)

52.5 (15.5)

0.99 (0.99–1.0)

0.005

0.99 (0.98–0.99)

0.0001

52.4 (15.0)

0.98 (0.98–0.99)

<0.0001

0.98 (0.97–0.98)

<0.0001

Sex, no. (%)

          

 Male

1418/2133 (66.5)

Ref.

-

-

-

297/5947 (5.0)

Ref.

-

Ref.

-

 Female

1021/1524 (67.0)

1.0 (0.89–1.2)

0.74

-

-

284/9084 (3.1)

0.61 (0.52–0.73)

<0.0001

0.58 (0.49–0.70)

<0.0001

Race/ethnicity, no. (%)

          

 White

1776/2645 (67.2)

Ref.

-

Ref.

-

392/10,523 (3.7)

Ref.

-

-

-

 Hispanic

324/486 (66.7)

0.98 (0.80–1.2)

0.84

0.92 (0.75–1.1)

0.45

78/1833 (4.3)

1.1 (0.90–1.5)

0.27

-

-

 Black

196/333 (58.9)

0.70 (0.56–0.88)

0.003

0.69 (0.55–0.88)

0.002

51/1759 (2.9)

0.77 (0.57–1.0)

0.09

-

-

 Asian

41/50 (82.0)

2.2 (1.1–4.6)

0.03

2.0 (0.98–4.3)

0.06

35/458 (7.6)

2.1 (1.5–3.1)

<0.0001

-

-

 Other

102/143 (71.3)

1.2 (0.8–1.8)

0.23

1.0 (0.72–1.6)

0.79

25/458 (5.5)

1.5 (0.98–2.3)

0.06

-

-

Residence, no. (%)

          

 US

2332/3510 (66.4)

Ref.

-

-

-

564/14,580 (3.9)

Ref.

-

Ref.

-

 Outside US

107/147(72.8)

1.4 (0.93–2.0)

0.11

-

-

17/451 (3.8)

0.97 (0.59–1.6)

0.92

0.51 (0.30–0.90)

0.02

HBV risk factor, no. (%)

          

 No

1683/2603 (64.7)

Ref.

-

Ref.

-

321/10,694 (3.0)

Ref.

-

Ref.

 

 Yes

756/1054 (71.7)

1.4 (1.2–1.6)

<0.0001

1.3 (1.1–1.5)

0.001

260/4337 (6.0)

2.1 (1.7–2.4)

<0.0001

2.5 (2.1–3.0)

<0.0001

Chemotherapy type, no. (%)

          

 Non-rituximab

1191/1854 (64.2)

Ref.

-

Ref.

-

469/14,857 (3.2)

Ref.

-

Ref.

-

 Rituximab

1248/1803 (69.2)

1.2 (1.1–1.4)

0.001

1.3 (1.2–1.5)

<0.0001

112/174 (64.4)

55.4 (40.1–76.6)

<0.0001

62.0 (44.1–87.0)

<0.0001

Timing of first chemotherapyc

          

 Period 1

1428/2312 (61.8)

Ref.

-

Ref.

-

326/9521 (3.4)

Ref.

-

Ref.

- 

 Period 2

829/1101 (75.3)

1.9 (1.6–2.2)

<0.0001

2.0 (1.6–2.3)

<0.0001

208/4602 (4.5)

1.3 (1.1–1.6)

0.001

1.3 (1.1–1.6)

0.003

 Period 3

182/244 (74.6)

1.8 (1.4–2.4)

<0.0001

1.9 (1.4–2.6)

<0.0001

47/908 (5.2)

1.5 (1.1–2. 1)

0.007

1.7 (1.2–2.3)

0.003

  1. Abbreviations: HBV hepatitis B virus, OR odds ratio, CI confidence interval, Ref., reference.
  2. aHBV screening means that both hepatitis B surface antigen (HBsAg) test and antibody to hepatitis B core antigen (anti-HBc) test were ordered.
  3. bExcludes patients with primary liver cancer.
  4. cPeriod 1: 1/1/04 through 12/18/2008; period 2, 12/19/2008 through 9/30/2010; period 3, 10/1/2010 through 4/30/11.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us